Bio-Thera Solutions (688177) Stock Overview
A biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
688177 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bio-Thera Solutions, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.10 |
| 52 Week High | CN¥36.32 |
| 52 Week Low | CN¥16.00 |
| Beta | 0.34 |
| 1 Month Change | -15.40% |
| 3 Month Change | -27.77% |
| 1 Year Change | -35.39% |
| 3 Year Change | -39.72% |
| 5 Year Change | -35.70% |
| Change since IPO | -73.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688177 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -5.6% | -4.2% | -1.9% |
| 1Y | -35.4% | -25.5% | 28.6% |
Return vs Industry: 688177 underperformed the CN Biotechs industry which returned -25.5% over the past year.
Return vs Market: 688177 underperformed the CN Market which returned 28.7% over the past year.
Price Volatility
| 688177 volatility | |
|---|---|
| 688177 Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 688177 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688177's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1,426 | Shengfeng Li | www.bio-thera.com |
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer; TOFIDENCE for the treatment of rheumatoid arthritis, polyarticular and systemic juvenile idiopathic arthritis, and cytokine release syndrome; and BETAGRIN for the treatment of acute coronary syndromes. The company also develops BAT2206, a biosimilar drug candidate used to treat psoriasis, Crohn’s disease, and ulcerative colitis; BAT2306 to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis; and BAT4406F, BAT6026, BAT2606, and BAT2506 for treatment of various autoimmune diseases.
Bio-Thera Solutions, Ltd. Fundamentals Summary
| 688177 fundamental statistics | |
|---|---|
| Market cap | CN¥6.67b |
| Earnings (TTM) | -CN¥390.44m |
| Revenue (TTM) | CN¥980.25m |
Is 688177 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688177 income statement (TTM) | |
|---|---|
| Revenue | CN¥980.25m |
| Cost of Revenue | CN¥196.83m |
| Gross Profit | CN¥783.42m |
| Other Expenses | CN¥1.17b |
| Earnings | -CN¥390.44m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 79.92% |
| Net Profit Margin | -39.83% |
| Debt/Equity Ratio | 348.6% |
How did 688177 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/27 15:21 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio-Thera Solutions, Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Yinglan Shu | Haitong International Research Limited |
| Qi Jiang | Zhongtai Securities Co. Ltd. |